🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million infections per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the highly restricted treatment choices currently available.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Experts anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization marks a significant shift in the therapy of highly resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to data released by a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which combines two antibiotics. The research enrolled over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have voiced optimism. The availability of a single-dose, oral treatment such as this is seen as a "game-changer" for public health efforts. This is considered vital to alleviate the strain of the disease for individuals and to halt the transmission of untreatable gonorrhoea globally.